Building on Radiant Pharmaceuticals Limited’s 20-year legacy of providing quality imported oncology products, Pharmacil Limited has achieved a significant milestone with the introduction of its first two locally manufactured biotech products, PrezuMab™ (Pembrolizumab) 100 mg and ImmunoMab™ (Nivolumab) 100 mg & 40 mg. This development marks an important step in expanding the company’s oncology portfolio and strengthening its commitment to advancing cancer care in Bangladesh.
To commemorate this milestone, Pharmacil Limited organized a series of scientific conferences focusing on the evolving role of immunotherapy in cancer treatment. The conferences featured Dr. Kenneth Sooi Wei Xiong, a distinguished international speaker, who shared valuable scientific insights into advancements in cancer immunotherapy, emerging treatment approaches, and their clinical significance in modern oncology practice.
The scientific sessions brought together distinguished oncologists and healthcare professionals from across Bangladesh, providing a platform for knowledge sharing, scientific discussions, and professional engagement. The active participation and valuable contributions of the attendees made the events both insightful and memorable.
The introduction of these locally manufactured biotech products reflects Pharmacil Limited’s continued efforts to strengthen its oncology portfolio and contribute to the advancement of cancer treatment options in Bangladesh.
Through continued scientific engagement and a commitment to quality and innovation, Radiant Pharmaceuticals Limited and Pharmacil Limited remain dedicated to supporting healthcare professionals and contributing to the future of oncology care in the country.